Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 21, 2012

View Archived Issues

Afatinib demonstrates significant improvements in PFS in the LUX-lung 3 phase III trial

Korean researchers patent novel antiviral compositions

Janssen Pharmaceutica presents new BACE1 inhibitors

Treventis prepares new anti-amyloid compounds

Novel cannabinoid CB1 receptor allosteric modulators discovered at University of Aberdeen

New efflux pump inhibitors for bacterial infections disclosed

Theravance presents new dual MABA bronchodilators for COPD

Ten major pharma companies form nonprofit organization

Almirall launches aclidinium in Europe

Cancer Therapeutics CRC synthesizes novel FADK inhibitors

Bayer submits European MAA for contraceptive patch

Identification of a new series of potent and selective NS5B inhibitors

Patrys cleared to commence phase I/IIa PAT-SM6 study

Murdoch Children's Research Institute receives grant to fight rotavirus

Intercell reports outcome of vaccine enhancement patch study in influenza

Plasma serotonin as indicator of stable heart disease outcomes

Scripps Research Institute receives grant for HIV research

The Leukemia & Lymphoma Society to support BET inhibitor program

Bayer College of Medicine presents novel Ndufs4-mutant mouse model

Sanofi and the TB Alliance to accelerate tuberculosis drug discovery

Cytochroma begins first of two identical phase III studies of CTAP-101

FDA approves sNDA for Aerospan inhalation aerosol

Dyax grants Kadmon exclusive license for anticancer candidate

Second phase I study confirms GAL-021's effects on respiration

Biovest provides update on planned MAA for NHL vaccine candidate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...